Clinical trials: Tumor Gastric
Early Gastric Cancer
Explainable Machine Learning for Predicting Early Gastric Cancer
Abstract Background: Early detection of gastric cancer is crucial for improving patient survival rates. Currently, the primary method for diagnosing early-stage gastric cancer is endoscopy, which has various limitations.
- Trial name
- NCT07047937
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Wenzhou Central Hospital
Gastric Cancer
S-1-induced Lacrimal Drainage Obstruction
S-1 is an effective drug in gastric cancer (GC) for palliative chemotherapy in Eastern and Western patients. Recently, S-1 has been also reported to be an effective adjuvant therapy for GC patients who received D2 surgery in…
- Trial name
- NCT01486472
- Testing
- S-1
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Bundang Hospital
Gastric Cancer
Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer
To explore whether adding olanzapine to paclitaxel chemotherapy could improve chemotherapy tolerance and improve patient quality of life and prolong treatment failure time (TTF) in advanced gastric cancer after failure of…
- Trial name
- NCT03575637
- Testing
- Olanzapine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University
Esophageal Cancer, Gastric Cancer
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601705
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Gastric Cancer
Biological Therapy in Treating Patients With Advanced Cancer
RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT00005956
- Testing
- HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Peritoneal Carcinomatosis, Gastric Cancer
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients.
- Trial name
- GASPACCO (NCT04595929)
- Testing
- Staging laparoscopy, 5-Fluorouracil, Leucovorin
- Where
- Russia
- Volunteers
- 304 people
- Sponsor
- St. Petersburg State Pavlov Medical University
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab…
- Trial name
- NCT06764875
- Testing
- Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab
- Where
- 304 sites in United States, Argentina and 26 more
- Volunteers
- 840 people
- Sponsor
- AstraZeneca
Gastric Neoplasia
High Definition Endoscopy and Optic Enhancement Endoscopy in Gastric Neoplasia: A Prospective Study
The aim of the study is to evaluate the diagnostic value of high definition endoscopy and optic enhancement in gastric neoplasia.
- Trial name
- NCT02863965
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong University
Melanoma, NSCLC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for…
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer
- Trial name
- NCT04114136
- Testing
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dan Zandberg
Gastric Cancer
A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer
Although Pembrolizumab plus trastuzumab and chemotherapy is the standard of care for first-line treatment of HER2-positive advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer,there is no established therapy…
- Trial name
- NCT05241899
- Testing
- Fruquintinib + RC48
- Where
- China
- Volunteers
- 56 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
HER2-positive Breast Cancer and Gastric Cancer
Clinical Study of 68Ga Labeled HER2 Affibody Analogues
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 68Ga labeled HER2 Affibody analogues and preliminarily evaluate its diagnosis value in patients with breast…
- Trial name
- NCT05411432
- Testing
- 68Ga labeled HER2 Affibody
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA).
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
- Trial name
- NeoTISLEGA (NCT07059299)
- Testing
- Tislelizumab, FLOT Chemotherapy
- Where
- 4 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gastrointestinal Cancer, Rectal Cancer
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients
To demonstrate the effectiveness of epoetin alfa on reduction in red blood cell transfusions in gastric and rectal cancer patients undergoing preoperative chemoradiation therapy followed by surgery.
- Trial name
- NCT00254436
- Testing
- Procrit (epoetin alfa)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative gastric cancer
- Trial name
- NCT00209664
- Testing
- irinotecan, S-1
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Gastric Cancer
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy.
- Trial name
- NCT05871099
- Testing
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- China
- Volunteers
- 616 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Gastric Neoplasm
GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110
The purpose of this study is to evaluate the role of splenectomy in potentially curative total gastrectomy for proximal gastric carcinoma in terms of survival benefit and post-operative morbidity.
- Trial name
- NCT00112099
- Testing
- Surgery: Splenectomy, Surgery: Spleen-preservation
- Where
- 35 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Haruhiko Fukuda
Fundic Gland Polyps
Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs
The class of proton pump inhibitor (PPI) medications such as omeprazole has proven extremely effective in the treatment and prevention of gastric and duodenal ulcers.
- Trial name
- NCT01130363
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
This trial is An open-label, multicohort, multicenter clinical study aimed at evaluating the efficacy and safety of the cadonilimab combination regimen in the treatment of advanced HER-2 positive gastric/gastroesophageal junction…
- Trial name
- NCT06650332
- Testing
- cadonilimab, Trastuzumab, XELOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhejiang Cancer Hospital
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
This phase II trial is studying how well bortezomib with or without irinotecan works in treating patients with gastroesophageal junction or stomach cancer that can not be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00061932
- Testing
- bortezomib, irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.